As previously mentioned, the approved drug tofersen is an ASO designed with the aim of reducing SOD1 protein levels for the treatment of SOD1-ALS patients, and initially brought hope for a successful gene therapy (Miller Timothy et al., 2022). This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.